Fig. 6

Isovitexin inhibits HCSLC carcinogenicity and stemness via the MnSOD/FoxM1 axis. HCSLCs or those expressing shMnSOD were transduced with Ad-FoxM1. a Immunoblotting performed with anti-MnSOD and anti-FoxM1 antibodies, with β-actin antibodies used as loading control; b and c Formed spheres and colonies (Scale bar, 200 μm); d Immunoblotting for CD133, CD44, ALDH1, Bmi1, Nanog and Oct4 in HCSLCs untreated (Mock), and transduced with Ad-shMnSOD and/or Ad-FoxM1. HCSLCs expressing shMnSOD were transduced with Ad-FoxM1 and incubated with or without isovitexin (ISOV; 10 μM). e Immunoblotting performed with anti-MnSOD and anti-FoxM1 antibodies, with β-actin antibodies as a loading control; f and g Formed spheres and colonies (Scale bar, 200 μm); h Immunoblotting for CD133, CD44, ALDH1, Bmi1, Nanog and Oct4 in MHCC97H cells transduced with Ad-shMnSOD and/or Ad-FoxM1 and incubated in the absence or presence of ISOV